Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2020-04-22 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 169.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 31 March 2020. It includes actual financial data such as receipts, payments, cash equivalents, and financing facilities. The document is approximately 9,948 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. The presence of detailed cash flow data and compliance statements confirms it is a quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-04-22 English
Quarterly Activities Report 3 pages 149.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'REPORT ON ACTIVITIES FOR THE QUARTER ENDED 31 MARCH 2020' and details the company's activities and progress during the quarter, including research programs, expenditures, and corporate updates. It references the quarter ended 31 March 2020, indicating it is a quarterly report. The document contains substantive information about financial expenditures and operational progress, not just an announcement or summary. It is not a full annual report, audit report, or earnings release but a comprehensive quarterly activity report with financial and operational details. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (5893 characters) supports it being a full report rather than a brief announcement or certification.
2020-04-22 English
R&D Tax Refund Received 1 page 114.9KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Biotron Limited regarding receipt of an R&D Tax Incentive refund for the 2018/19 financial year. It is a brief notification about a government cash refund related to research and development expenditure. The document is only 1 page and 1123 characters long, indicating it is not a detailed financial report or comprehensive filing. It does not contain financial statements, management discussion, or detailed financial data. It is an update on a financing-related event (receipt of a government cash refund) that impacts the company's cash position. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and cash inflows from government incentives.
2020-03-18 English
BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS 3 pages 756.9KB
Investor Presentation Classification · 95% confidence The document is a detailed communication from Biotron Limited regarding the results of a Phase 2 clinical trial of their drug BIT225 in combination with antiretroviral therapy for HIV-1 infection. It includes extensive scientific data, methodology, results, and conclusions about the immune function restoration observed in the trial. The document is not a brief announcement or a summary but contains substantive clinical trial data and analysis. It is not a regulatory filing, certification, or announcement of a report publication. The content is scientific and clinical trial results focused, which aligns with a detailed report on clinical trial outcomes rather than financial or governance reporting. Given the nature of the document, it best fits the category of an Investor Presentation (IP) because it is a detailed presentation of clinical trial data intended for investors and stakeholders to understand the progress and potential of the drug development program. It is not an Annual Report, Earnings Release, or other financial filing. Therefore, the classification is Investor Presentation (IP) with high confidence.
2020-03-11 English
Half Yearly Report and Accounts 21 pages 1.8MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2019' and includes detailed financial statements such as the Condensed Interim Statement of Profit or Loss, Statement of Financial Position, Cash Flows, and Notes to the Financial Statements. It also contains a Directors' Report and an Independent Auditor’s Review Report. The document references compliance with Listing Rule 4.2A and is clearly a comprehensive financial report for a half-year period, not just an announcement or summary. The length is substantial (15,000 characters), and it contains substantive financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2020-02-26 English
Letter to Shareholders 3 pages 252.4KB
Regulatory Filings Classification · 95% confidence The document is a shareholder update letter from Biotron Limited dated February 2020. It discusses ongoing research programs, updates on antiviral drug development, intellectual property filings, and upcoming conference presentations. There are no financial statements, regulatory certifications, voting results, or formal report filings included. The document is a communication sent to shareholders providing business and program updates rather than a formal financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other formal filing type. It is also not a short announcement of a report publication but a substantive update letter. Therefore, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement and shareholder communication that does not fit other specific categories.
2020-02-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.